Biofrontera AG reported Q1 2025 revenue of USD 8.59 million, with a gross profit of USD 5.51 million and a gross margin of 64.2%. However, the company posted a operating loss of USD 4.55 million and a net loss of USD 4.20 million, producing an EPS of -0.76. The quarter shows a modest year-over-year revenue increase (+8.7%) but a sharp sequential decline (-31.6%), reflecting seasonality or mix effects in a small-cap dermatology-focused biopharma. Operating expenses remained elevated, with SG&A at USD 8.65 million and R&D at USD 1.21 million, driving negative EBITDA (-USD 4.55 million). Cash burn was meaningful, with net cash used in operating activities of USD 4.12 million and free cash flow of USD -4.12 million, leaving USD 1.99 million in cash at period end. Equity is constrained, with total stockholders’ equity of USD 0.47 million and net debt of USD 3.08 million, despite a sizable other stockholders’ equity line that largely offsets retained earnings. The result underscores near-term profitability challenges, but the company retains a favorable gross margin and a development pipeline, including Ameluz and BF-RhodoLED, which could drive future growth if monetization and cost controls improve. The strategic pivot hinges on leveraging partnerships (notably with Maruho) and accelerating market penetration in key geography through product launches and new indications, while preserving liquidity to fund operations until a meaningful earnings inflection occurs.